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Abstract
KRIT1 is a gene responsible for Cerebral Cavernous Malformations (CCM), a major cerebrovascular disease characterized by
abnormally enlarged and leaky capillaries that predispose to seizures, focal neurological deficits, and fatal intracerebral
hemorrhage. Comprehensive analysis of the KRIT1 gene in CCM patients has suggested that KRIT1 functions need to be
severely impaired for pathogenesis. However, the molecular and cellular functions of KRIT1 as well as CCM pathogenesis
mechanisms are still research challenges. We found that KRIT1 plays an important role in molecular mechanisms involved in
the maintenance of the intracellular Reactive Oxygen Species (ROS) homeostasis to prevent oxidative cellular damage. In
particular, we demonstrate that KRIT1 loss/down-regulation is associated with a significant increase in intracellular ROS
levels. Conversely, ROS levels in KRIT12/2 cells are significantly and dose-dependently reduced after restoration of KRIT1
expression. Moreover, we show that the modulation of intracellular ROS levels by KRIT1 loss/restoration is strictly correlated
with the modulation of the expression of the antioxidant protein SOD2 as well as of the transcriptional factor FoxO1, a
master regulator of cell responses to oxidative stress and a modulator of SOD2 levels. Furthermore, we show that the KRIT1-
dependent maintenance of low ROS levels facilitates the downregulation of cyclin D1 expression required for cell transition
from proliferative growth to quiescence. Finally, we demonstrate that the enhanced ROS levels in KRIT12/2 cells are
associated with an increased cell susceptibility to oxidative DNA damage and a marked induction of the DNA damage
sensor and repair gene Gadd45a, as well as with a decline of mitochondrial energy metabolism. Taken together, our results
point to a new model where KRIT1 limits the accumulation of intracellular oxidants and prevents oxidative stress-mediated
cellular dysfunction and DNA damage by enhancing the cell capacity to scavenge intracellular ROS through an antioxidant
pathway involving FoxO1 and SOD2, thus providing novel and useful insights into the understanding of KRIT1 molecular
and cellular functions.
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Introduction
KRIT1 was originally identified through a yeast two-hybrid
screening designed to find interacting partners of the Ras-like
GTPase Rap1 [1], and subsequently found to be one out of three
genes responsible for causing Cerebral Cavernous Malformations
(CCM; OMIM 116860) [2,3,4]. This is a major cerebrovascular
disease, with a prevalence of 0.1%–0.5% in the general
population, which may occur sporadically or be inherited as an
autosomal dominant condition with incomplete penetrance [5]. It
is characterized by abnormally enlarged and often leaky capillary
cavities that predispose to seizures, focal neurological deficits, or
fatal intracerebral hemorrhage [6,7]. The CCM disease is
diagnosed through the Magnetic Resonance Imaging (MRI)
technique, which usually reveals the presence of either single or
multiple lesions in sporadic and familial cases, respectively [7].
The majority of CCM lesions remains clinically and biologically
quiescent during the host’s lifetime, except for brief phases of
apparent angiogenic proliferative activity and hemorrhage [8].
Symptomatic disease occurs in only 20–30% of affected individ-
uals and typically begins in the third through fifth decades of life,
although lesions have been described in all age groups. To date
there are not direct therapeutic approaches, besides the surgical
removal of accessible lesions in patients with recurrent hemor-
rhage or intractable seizures.
As detected by in situ hybridization and immunohistochemical
studies, KRIT1 is expressed neither specifically nor strongly in the
endothelium. Indeed, it is widely expressed in human and mouse
tissues, including the nervous system, the thymus, various
epithelia, and ossification centers, suggesting a widespread
functional significance, not restricted to vascular tissues [9,10,11].
On the other hand, genetic studies in mice and zebrafish have
shown that the loss of KRIT1 leads to embryonic lethal
cardiovascular defects owing to primary endothelial cell dysfunc-
tions, suggesting that KRIT1 plays critical endothelial cell-
autonomous roles [12,13,14]. However, the putative molecular
and cellular functions of KRIT1 protein in endothelial cells
remain controversial as the vascular defects observed in mouse and
zebrafish KRIT1 mutants have been attributed to either abnormal
cell-cell junctions [13] or altered cell spreading associated with
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ultrastructurally normal cell-cell contacts [12]. Moreover, further
issues emerge from molecular studies showing that KRIT1 can
regulate either VE-cadherin-mediated endothelial cell-cell junc-
tion integrity [15,16] or b1 integrin-mediated endothelial cell
proliferation [17]. Thus, the physiological functions of KRIT1 as
well as the CCM pathogenesis mechanisms remain challenges for
basic and translational research.
Comprehensive analysis of KRIT1 gene in patients with CCMs
has led to the identification of more than 90 distinct mutations
predicted to lead mainly to a premature stop codon [2,18],
suggesting that KRIT1 function needs to be severely impaired for
pathogenesis. Indeed, recent molecular and immunohistochemical
data suggest that CCM lesion genesis requires complete loss
of KRIT1 function through a two-hit molecular mechanism
[19,20,21,22]. However, both clinical reports and experiments in
animal models have raised the possibility that the second hit may
not be limited to genetic disruptions but could also take the form of
recurrent exposure of the particularly sensitive brain vasculature to
local cellular stresses [23,24,25]. Among the cellular stresses that
might account for a sort of environmental second hit, triggering
CCM lesion formation in sensitive vascular areas of CCM
mutation carriers, there is oxidative stress. This may be caused
locally by an imbalance between the production of reactive oxygen
species (ROS) and the ability of cellular antioxidant mechanisms
to readily detoxify the reactive intermediates or easily repair the
resulting damage. Indeed, oxidative stress has been clearly
implicated in vascular remodeling and endothelial dysfunction
associated with cerebrovascular diseases [26], raising the possibil-
ity that it might represent an additive event involved in CCM
pathogenesis. Consistently, a potential relationship between
KRIT1 and oxidative stress can be envisaged from data in
Caenorhabditis elegans showing the KRIT1 ortholog influences the
nuclear localization and life span extension function of DAF-16
[27], a member of the Forkhead box O (FoxO) protein family,
which is known to play a major role in cellular responses to
oxidative stress [28,29].
To investigate whether KRIT1 plays a role in the maintenance
of a proper intracellular ROS homeostasis, we combined the
complementary genetic knockout and RNA interference (RNAi)
knockdown technologies with biochemical analyses of molecular
pathways involved in cellular defenses against oxidative stress. We
show for the first time that KRIT1 is part of a signal transduction
pathway that regulates the steady-state levels of intracellular ROS
to prevent oxidative DNA damage, and raise the hypothesis that
CCM disease may result from an increased cell susceptibility to
microenvironmental oxidative challenges in sensitive microvascu-
lar districts of CCM mutation carriers.
Results
Establishment of KRIT12/2 MEF cell lines
Using a homologous recombination strategy we generated
KRIT1 knockout mice (Fig. 1A–D). Consistently with a previous
report [14], the homozygous KRIT1-null mutants died at an early
stage of embryonic development (E9.5) (Fig. 1C,D and unpub-
lished results).
KRIT12/2 and KRIT1+/+Mouse Embryonic Fibroblast (MEF)
cell lines were established from KRIT12/2 and KRIT1+/+ E8.5
mouse embryos, respectively, using the 3T3 protocol [30]. Western
blot analysis of whole cell lysates was used to confirm both the lack
of KRIT1 expression in KRIT12/2 MEF cells and the specificity
of two distinct KRIT1 polyclonal antibodies produced in our
laboratory (Fig. 2). One of these antibodies (K1) reacted with the
specific KRIT1 80 kDa band as well as with an additional 95 kDa
undetermined protein which served as an internal control for blot
normalization (Fig. 2A), whereas the other (K2) detected only the
specific 80 kDa protein (Fig. 2B).
Re-expression of KRIT1 in KRIT12/2 MEF cells
In order to obtain KRIT1-null and KRIT1-expressing MEF
cells with uniform genetic backgrounds to be used for comparative
molecular and cellular biology studies, KRIT12/2MEF cells were
infected with a lentiviral vector encoding either KRIT1
(pCCLsin.PPT.PGK.KRIT1.Wpre; Fig. 2C), to restore KRIT1
expression, or GFP (pCCLsin.PPT.PGK.EGFP.Wpre) [31] as a
control. The efficiency of distinct infections, evaluated as
percentage of GFP positive cells, was always greater that 80%.
Western blot analysis with the anti-KRIT1 antibody K2
confirmed the lack of KRIT1 expression in KRIT12/2 MEFs,
either uninfected (KRIT12/2) or infected with the GFP-
expressing control construct (Lv-GFP), and assessed KRIT1 re-
expression levels in KRIT1-transduced MEFs (Lv-KRIT1)
(Fig. 2D). Among the outputs of distinct stable infections, the
Lv-KRIT1 2/7, 10/6 and 9/6 cell populations, deriving from the
same KRIT12/2 MEF clone (A6), showed low, medium and high
KRIT1 expression levels, respectively (Fig. 2D), and were
therefore selected for further analysis. Remarkably, as shown also
in Fig. 2D, the KRIT1 expression level in wild-type MEFs
(KRIT1+/+) resulted intermediate between the Lv-KRIT1 2/7
and 10/6 cells.
KRIT1 regulates steady-state levels of intracellular ROS
The maintenance of highly regulated mechanisms to control
ROS levels is essential for normal cellular homeostasis. Indeed,
several experimental and clinical studies have clearly implicated
abnormal intracellular levels of ROS in promoting extensive
cellular damage and dysfunctions in most cell types, including
endothelial cells, as well as in the pathogenesis of human vascular
diseases, including cerebrovascular diseases [26,32], raising the
possibility that it might represent an additive event involved in
CCM pathogenesis.
To investigate whether KRIT1 plays a role in the regulation of
ROS metabolism, we compared the steady-state levels of
intracellular ROS in wild-type, KRIT12/2 and Lv-KRIT1 MEFs
using a well-established method based on the cell-permeable ROS-
sensitive fluorogenic probes 29,79-dichlorofluorescin diacetate
(DCFH-DA) and dihydroethidium (DHE) coupled with fluores-
cence microscopy and flow cytometry detection [33,34,35,36].
The probe DCFH-DA can be oxidized to the green fluorescent
product dichlorofluorescein (DCF) through its reaction with
distinct intracellular ROS, including hydrogen peroxide (H2O2),
peroxynitrite (OONO2) and lipid hydroperoxides (LOOH), and it
has been extensively used as an indicator of the degree of general
oxidative stress in cells [35,36]. On the other hand, the DHE
probe is more specific as it reacts essentially with superoxide
radicals (O2
?2) to form the red fluorescent product ethidium (Eth)
[33,35,36]. Fluorescence microscopy analysis (Fig. 3A,B) and
FACS quantification (Fig. 3C–H) showed that the steady-state
level of intracellular ROS was significantly elevated in KRIT12/2
MEFs compared with wild-type cells (Fig. 3A–D,G,H). Converse-
ly, ROS levels in KRIT12/2 cells were significantly reduced after
restoration of KRIT1 expression (Fig. 3A,B,E–H), indicating that
the effect on ROS levels in the KRIT12/2 cells is directly linked
to the loss of KRIT1 expression. Indeed, the reduction of
intracellular ROS levels was strictly correlated with the levels of
KRIT1 re-expression (compare Fig. 3E,F with Fig. 2D), suggesting
that KRIT1 plays a dose-dependent role in the intracellular
machinery that controls the redox balance.
KRIT1 Controls ROS Levels
PLoS ONE | www.plosone.org 2 July 2010 | Volume 5 | Issue 7 | e11786
KRIT1 modulates the expression levels of the antioxidant
protein SOD2
Changes in intracellular ROS levels are due to the imbalance
between generation of ROS and the defense ability of the various
antioxidant mechanisms [26,32].
Among the first and most important regulators of ROS levels
are the superoxide dismutase (SOD) enzymes [37,38], which play
primary roles in protecting and preserving cells against oxidative
stress via the scavenging of the superoxide anion (O2
?2), a
precursor of all reactive oxygen species, including the powerful
Figure 1. KRIT1 knockout by homologous recombination. A) Targeting strategy to generate the KRIT1 knockout allele (see Materials and
Methods for details). B) Southern blotting of EcoRV-digested genomic DNA with a 700 bp KRIT1 probe mapping downstream of the targeting vector.
The 16.8 and 9.5 Kb bands correspond to the wild-type (WT) and recombinant (Rec) allele, respectively. The 262 and 333 ES clones are heterozygous
for the recombinant allele. C–D) PCR genotyping of embryo (C) and newborn (D) mice. The 300 and 809 bp bands correspond to the wild-type (WT)
and recombinant (Rec) allele, respectively. Wt, Ht, Hm indicate wild-type, heterozygous, and homozygous genotypes, respectively. c-Wt and c-Ht are
positive controls. No homozygous mutant mice were born.
doi:10.1371/journal.pone.0011786.g001
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oxidants hydrogen peroxide (H2O2), peroxynitrite (OONO
2) and
hydroxyl radical (?OH) [26,39,40]. In addition, a second
important line of antioxidant defense system against ROS consists
of the catalase enzyme, which is responsible for the reduction of
H2O2 to H2O [26,40].
To test whether the elevated steady-state levels of intracellular
ROS found in KRIT12/2 cells were related to variations in
antioxidant defense mechanisms, we performed Western blot and
real-time quantitative PCR (RT-qPCR) analysis of the expression
levels of major antioxidant defense genes, including copper-zinc
superoxide dismutase (SOD1/Cu-ZnSOD), manganese superox-
ide dismutase (SOD2/MnSOD), and catalase, in KRIT12/2 and
Lv-KRIT1 MEFs.
The outcomes of these experiments showed that the expression
levels of SOD2 protein were significantly lower in KRIT12/2
Figure 2. Lentiviral re-expression of KRIT1 in KRIT12/2 MEF
cells. A–B) Western blot analysis of KRIT12/2 and KRIT1+/+ MEF cell
lysates assessing the lack of KRIT1 expression in KRIT12/2 MEF cells and
the detection of the specific 80 kDa band by two distinct anti-KRIT1
polyclonal antibodies (K1 and K2). The additional, undetermined 95 kDa
band detected by the K1 antibody (A) served as an internal control for
blot normalization. C) Lentiviral construct. The mouse KRIT1A cDNA
(GenBank AY464945) was subcloned into the lentiviral expression
vector pCCLsin.PPT.PGK.Wpre finally coding for the full-length KRIT1A
protein. D) Western blot analysis with the K2 antibody assessing KRIT1
re-expression levels in KRIT1-transduced MEFs (Lv-KRIT1) as compared
to wild type MEFs (KRIT1+/+). KRIT12/2MEFs, either uninfected (KRIT12/2)
or transduced with a GFP-coding lentiviral construct (Lv-GFP), were used
as negative controls. Notice that the distinct KRIT1-transduced cells
express either lower (Lv-KRIT1 2/7) or higher (Lv-KRIT1 10/6 and 9/6)
levels of KRIT1 than wild type MEFs (KRIT1+/+). Tubulin was used as
loading control.
doi:10.1371/journal.pone.0011786.g002
Figure 3. KRIT1 regulates steady-state levels of intracellular
ROS. A–B) Qualitative detection of the steady-state levels of
intracellular ROS by fluorescence microscopy. Wild-type (WT), KRIT12/2
(KRIT12/2) and KRIT1-transduced (Lv-KRIT1 9/6) MEFs grown under
standard conditions were analyzed by fluorescence microscopy 20 min
after the addition of the cell-permeable redox-sensitive fluorogenic
probe DCFH-DA (A) or DHE (B). The images were taken with a fixed short
exposure time and a high fluorescence intensity threshold value to avoid
saturation, and are representative of several independent experiments.
Notice that KRIT12/2 cells (panels b) showed significantly more intense
fluorescent signals than WT cells (panels a), indicating that they
contained higher levels of ROS. Conversely, ROS levels in KRIT12/2 cells
were reduced to near WT levels upon KRIT1 re-expression by lentiviral
infection (panels c). Scale bar represents 50 mm. C–H. Quantitative
determination of the steady-state levels of intracellular ROS by FACS
analysis. Wild-type (WT), KRIT12/2 (K2/2) and three distinct KRIT12/2 cell
populations re-expressing KRIT1 at low, medium and high levels,
respectively [Lv-KRIT1 2/7 (K2/7), 10/6 (K10/6) and 9/6 (K9/6)], were
grown under standard conditions and analyzed by FACS 20 min after the
addition of the DCFH-DA (C–F) or DHE (G,H) probes. Representative flow
cytometry profiles (C,E,G) and quantitative histograms of the mean
fluorescence intensity (M.F.I.) values (D,F,H) of n$5 independent FACS
experiments are shown. M.F.I. values were normalized to spontaneous
fluorescence of control cells untreated with the fluorogenic probes (Ctr)
and expressed as percentage of KRIT12/2 (K2/2) cells (6 SD). *P,0.001
versus KRIT12/2 cells. Notice that KRIT12/2 cells displayed the highest
content of intracellular ROS, whereas the re-expression of KRIT1 caused a
significant, expression level-dependent decrease in intracellular ROS
levels.
doi:10.1371/journal.pone.0011786.g003
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MEFs than in KRIT12/2 MEFs re-expressing KRIT1 (Fig. 4A).
Remarkably, a positive correlation between KRIT1 and SOD2
protein expression levels was also observed (Fig. 4A). In addition,
the same effect was also clearly demonstrated at the mRNA level
(Fig. 4B), suggesting that KRIT1 may play a role in controlling
SOD2 mRNA expression. In contrast, the re-expression of KRIT1
in KRIT12/2 MEFs did not affect significantly SOD1 and
catalase levels (Fig. 4C–D).
Taken together with the finding that KRIT1 plays a role in the
control of ROS steady-state levels, these results suggest that
KRIT1 may regulate intracellular ROS by modulating the level of
the antioxidant enzyme SOD2.
KRIT1 regulates FoxO1 expression
Among the regulators of ROS levels that act by modulating the
expression of antioxidant enzymes, the FoxO family of transcrip-
tion factors has been demonstrated to play a major, highly
conserved role [28,29,41]. In particular, it has been reported that
FoxO proteins protect cells from oxidative stress and contributes to
life span extension by lowering intracellular ROS through the
upregulation of SOD2 [42,43,44,45,46]. Furthermore, among
four members of the mammalian FoxO family, namely FoxO1,
FoxO3a, FoxO4, and FoxO6 [47], FoxO1 has been demonstrated
to play a crucial role both in the fine-tuning of the cell antioxidant
system [42,46,48] and in the maintenance of endothelial stability
and vascular homeostasis [49,50,51,52]. On the other hand, a
study in C. elegans has shown that kri-1, the worm ortholog of
KRIT1/CCM1, is required for germline removal-dependent life
span extension through regulation of DAF-16, the worm ortholog
of mammalian FoxO genes [27]. Taken together, these observa-
tions prompted us to investigate whether FoxO1 levels/activity
were affected by KRIT1. In particular, since FoxO expression/
activity can be influenced by cell culture conditions, including
the presence of serum factors [47,53,54], we analyzed FoxO1
Figure 4. KRIT1 modulates the expression levels of the antioxidant protein SOD2. KRIT12/2 MEFs, either uninfected (K2/2) or GFP-
transduced (K2/2GFP), and three distinct KRIT1-transduced MEF populations re-expressing KRIT1 at low, medium and high levels, respectively (K2/7,
K10/6 and K9/6), were grown under standard conditions and analyzed by Western blot and RT-qPCR as described in Materials and Methods. A)
Western blot analysis of the relative SOD2 and KRIT1 protein expression levels. KRIT1 protein levels in cell extracts were assessed using both the K1
(K1 pAb) and K2 (K1 pAb) antibodies. The additional, undetermined 95 kDa band detected by the K1 antibody (A, panel K1 pAb) served as internal
control for blot normalization. B–D) RT-qPCR analysis of SOD2 (B), SOD1 (C) and Cat (D) mRNA expression levels. The amount of each target mRNA
expressed in a sample was analyzed in triplicate using appropriate TaqManH gene expression assays (Roche), and normalized to the amounts of
internal normalization control transcripts (18S rRNA and GAPDH). Results are expressed as relative mRNA level units referred to the average value
obtained for the KRIT12/2 (K2/2) samples, and represent the mean (6 SD) of n$3 independent RT-qPCR experiments. *P,0.001 versus KRIT12/2
cells. Notice that KRIT1 re-expression in KRIT12/2 cells caused a significant, dose-dependent upregulation of SOD2 expression at both protein and
mRNA levels.
doi:10.1371/journal.pone.0011786.g004
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expression either in cells grown to confluence under standard
culture conditions, or in confluent cells serum-starved overnight
and either left untreated or stimulated with 10%FCS for 15 min.
Using quantitative real-time PCR (RT-qPCR) and Western blot
analyses, we found that FoxO1 mRNA (Fig. 5A) and protein
(Fig. 5B,C) levels were significantly lower in KRIT12/2 MEFs
(K2/2) than in KRIT12/2 MEFs re-expressing KRIT1 (K2/7,
K10/6 and K9/6) either when cells were assayed after reaching
confluence in standard culture conditions (Fig. 5A,B) or when
confluent cells were serum-starved (Fig. 5C, -FCS) or serum-
stimulated (Fig. 5C, +FCS), suggesting that the loss of KRIT1
affects FoxO1 expression independently of the presence of serum
factors.
Central to the regulation of FoxO1 level/activity is a complex
mechanism that regulates its phosphorylation-dependent nucleo-
cytoplasmic shuttling [47,53,54]. Indeed, under quiescent cell
culture conditions, FoxO1 is predominantly unphoshorylated and
transcriptionally active. Conversely, in response to mitogenic
stimulators, including serum and specific growth factors, FoxO1
undergoes an Akt-primed sequential phosphorylation at a series of
regulatory Ser/Thr residues which dictates FoxO1 nuclear export
and sequestration or degradation in the cytoplasm, thereby
inhibiting its transcriptional activity [47,53].
The inhibitory phosphorylation of FoxO1 is easily detectable, as
the phosphorylated form has a slower electrophoretic mobility
than the unphosphorylated one [55,56,57]. Strikingly, besides the
difference in FoxO1 expression levels, our Western blot analyses
highlighted an increased ratio of phosphorylated (p-FoxO1) to
unphosphorylated (FoxO1) form of FoxO1 in KRIT12/2 versus
Lv-KRIT1 MEFs (Fig. 5B). Moreover, the Akt priming of the
phosphorylation-dependent electrophoretic mobility shift of
FoxO1 was clearly demonstrated by the abrogation of this shift
upon cell pretreatment with LY294002, an inhibitor of the PI3K/
Akt pathway (Fig. 5D), suggesting that the loss of KRIT1 leads to
Figure 5. KRIT1 regulates FoxO1 expression and activity.Wild-type (WT), KRIT12/2MEFs (K2/2) and Lv-KRIT1 MEFs re-expressing KRIT1 at low,
medium and high levels, respectively (K2/7, K10/6 and K9/6), were analyzed by RT-qPCR and Western blot as described in Materials and Methods. A)
RT-qPCR analysis of FoxO1 mRNA expression levels. Results are expressed as relative mRNA level units referred to the average value obtained for the
KRIT12/2 (K2/2) samples, and represent the mean (6 SD) of n$3 independent RT-qPCR experiments. *P,0.001 versus KRIT12/2 cells. Notice that
KRIT1 re-expression in KRIT12/2 cells caused a significant, dose-dependent upregulation of FoxO1 mRNA levels. B–D) Western blot analysis of FoxO1
protein expression in confluent KRIT12/2 and Lv-KRIT1 MEFs. Cells were grown to confluence in standard culture conditions, and lysed (B).
Alternatively, confluent cells were serum-starved overnight (C) and either left untreated (-FCS) or treated with 10% FCS for 15 min (+FCS) before lysis.
In the FoxO1 blots, the upper and lower bands are the phosphorylated and unphosphorylated forms of FoxO1, respectively. (D) To demonstrate that
the upward electrophoretic mobility shift of FoxO1 was Akt-dependent, confluent cells were serum-starved overnight and treated with 10% FCS for
15 min (+FCS) either in the absence (-LY) or in the presence (+LY) of the PI3K/Akt pathway inhibitor LY294002. Phospho-Akt levels were determined
with an antibody to phospho-serine 473. The undetermined 95 kDa band detected by the K1 antibody and Tubulin served as loading controls. Notice
that the expression level of FoxO1 is reduced and the ratio of phosphorylated to unphosphorylated forms of FoxO1 is increased in KRIT12/2 MEFs
compared with Lv-KRIT1 MEFs.
doi:10.1371/journal.pone.0011786.g005
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an increased Akt-dependent phosphorylation of FoxO1, thus
affecting its activity and prompting its proteasomal degradation.
Consistently, the need for KRI-1 in C. elegans life span extension is
overcome by a mutant DAF-16 protein (DAF-16AM) lacking the
consensus Akt-phosphorylation sites through which the PI3K/Akt
pathway prevents DAF-16 nuclear localization, as well as by the
inhibition of the PI3K/Akt pathway [27], suggesting that KRI-1
function is dispensable when DAF-16 is unphosphorylated on the
Akt-consensus sites, and raising the possibility that KRI-1
promotes DAF-16 function by preventing or counteracting its
Akt-mediated phosphorylation [27]. In the light of this seminal
work, and considering the well established link between life span
extension and ROS detoxification, we performed additional
experiments aimed at better define the role of the PI3K/Akt
pathway in the relationship between KRIT1 loss and FoxO1
downregulation. Western blotting analysis of the phosphorylated,
active form of Akt in KRIT12/2 and KRIT1-expressing MEFs
grown in standard culture conditions showed that the basal levels
of the phosphorylated form of Akt were higher in KRIT12/2
MEFs than in their Lv-KRIT1 counterparts (Supplementary Fig.
S1A). Moreover, this difference resulted further enhanced upon
oxidative challenge by cell treatment with H2O2 (Supplementary
Fig. S1B). In addition, Western blotting analysis of the effects of
the PI3K/Akt pathway inhibition onto FoxO1 expression levels
showed that the enhanced FoxO1 downregulation found in
KRIT12/2 cells resulted sensitive to the PI3K selective inhibitor
LY294002 (Supplementary Fig. S1C,D). In particular, a short-
term (30 min) cell pre-treatment with LY294002 resulted in the
abrogation of the phosphorylation-dependent electrophoretic
mobility shift of FoxO1 induced by acute (15 min) serum
stimulation (Supplementary Fig. S1C), whereas a long-term
(16 hrs) treatment counteracted the serum-dependent FoxO1
downregulation resulting in a slight but significant accumulation
of FoxO1 (Supplementary Fig. S1D).
Taken together, these results demonstrate a positive correlation
between KRIT1 expression and FoxO1 levels/activity, and
suggest that the KRIT1 loss-dependent downregulation of FoxO1
can be attributable, at least in part, to a KRIT1 loss-dependent
enhanced activation of Akt.
As an additional potential player in the relationship between
KRIT1 and FoxO1, we investigated the role of SirT1, a FoxO1
interactor known to potentiate FoxO1-mediated transcription of
the antioxidant gene SOD2 [58]. Co-immunoprecipitation and
Western blotting analysis showed that SirT1 protein levels in
KRIT12/2 MEFs (K2/2) were the same as in KRIT12/2 MEFs
re-expressing KRIT1 (K9/6) (Supplementary Fig. S2, panel
SirT1), suggesting that KRIT1 does not influence the expression
of SirT1. Consistently, KRIT1 was not present in SirT1
immunocomplexes even when expressed at high levels (K9/6
MEFs) (Supplementary Fig. S2, panel KRIT1). On the contrary, a
modest but significant co-immunoprecipitation of FoxO1 with
SirT1 was observed in KRIT1-expressing MEFs but not in
KRIT12/2 MEFs (Supplementary Fig. S2, panel FoxO1).
Whereas this difference is likely attributable to the significant
difference in FoxO1 expression levels between K9/6 and K2/2
MEFs (Supplementary Fig. S2, panel FoxO1, total extract), it
indicates that the expression of KRIT1 favors the SirT1/FoxO1
interaction, which, in turn, might contribute to the enhanced
ability to detoxify endogenous ROS that characterizes KRIT1-
expressing cells.
Collectively, these results, although do not rule out the
possibility that KRIT1 may control FoxO1 expression through
an indirect modulation of SirT1 function, support the interpre-
tation that KRIT1, by preventing the Akt-mediated inactivation
and downregulation of FoxO1, may favor the SirT1/FoxO1
interaction, which, in turn, could promote the shifting of FoxO1
functions towards resistance to oxidative stress.
siRNA–mediated knockdown in endothelial cells confirms
the role of KRIT1 in controlling FoxO1 and SOD2
expression
To test whether the role of KRIT1 in controlling FoxO1 and
SOD2 expression was supported by experimental procedures
alternative and complementary to the genetic knockout technol-
ogy, as well as confirmed in cell types more relevant to the CCM
disease, we used the RNAi technology to knockdown KRIT1
expression in Human Umbilical Vein Endothelial Cells (HUVEC).
To this end, HUVEC were reverse transfected with two distinct
KRIT1-specific short interfering RNA (siK655 and siK469) or
Negative Control siRNA (siNC) and analyzed by RT-qPCR.
As compared with negative controls, HUVEC transfected with
the two distinct KRIT1-specific siRNA exhibited levels of KRIT1
mRNA expression reduced by ,50%, indicating a partial
knockdown effectiveness (Fig. 6A). Nevertheless, the knockdown
of KRIT1 in HUVEC resulted in a concomitant, significant
reduction of the mRNA levels of both FoxO1 (Fig. 6B) and SOD2
(Fig. 6C), but not of other FoxO family members, such as FoxO4
(Fig. 6D), nor of other antioxidant defense genes, including SOD1
(Fig. 6E) and catalase (Fig. 6F). Thus, although incomplete, the
level of KRIT1 knockdown achieved in HUVEC was sufficient to
cause a specific downregulation of FoxO1 and SOD2 mRNA
expression, confirming the positive correlation found through the
gene knockout approach (Fig. 4B and 5A), and demonstrating that
KRIT1 was involved in the control of FoxO1 and SOD2
expression levels in endothelial cells.
KRIT1 facilitates the FoxO-mediated cell transition from
proliferative growth to quiescence
Increased expression and transcriptional activity of FoxO
proteins is often associated with cell cycle exit and entry into
quiescence through the regulation of genes that control these
processes, such as cyclin D1, cyclin G2, p27Kip1, and p130Rb2
[59,60,61,62,63]. In particular, it has been shown that FoxO-
induced withdrawal from the cell cycle occurs in early G1 phase
and involves transcriptional downregulation of cyclin D1, a crucial
regulator of cell cycle progression through the G1 phase.
Conversely, inactivation of FoxO proteins by phosphorylation at
the conserved Akt sites triggers cell cycle progression by promoting
cyclin D1 expression [63]. Thereby, to investigate whether the
involvement of KRIT1 in the regulation of FoxO1 protein levels
and activity was also reflected at a functional level, we first
examined cyclin D1 expression in KRIT12/2 and Lv-KRIT1
MEF cultures grown to post-confluence. As detected by Western
blot, cyclin D1 protein levels were significantly higher in KRIT12/2
MEFs (K2/2) than in KRIT12/2MEFs re-expressing KRIT1 (K2/
7, K10/6 and K9/6) (Fig. 7A), indicating that the loss of KRIT1
leads to the upregulation of cyclin D1 expression. Moreover, an
inverse relationship between KRIT1 and cyclin D1 expression was
also clearly demonstrated at the mRNA level, as detected by RT-
qPCR (Fig. 7B), indicating that KRIT1 plays a role in controlling
cyclin D1 expression both at the protein and mRNA level.
Furthermore, RT-qPCR analyses demonstrated that the mRNA
levels of the cell cycle inhibitor p27Kip1, an additional marker of
FoxO1-mediated cell transition from proliferative growth to
quiescence [59,62,64,65], were higher in post-confluent Lv-KRIT1
than KRIT12/2 MEFs (Fig. 7C), suggesting that KRIT1 contrib-
utes to the upregulation of p27Kip1 associated with cell cycle exit.
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To assess whether KRIT1 was indeed involved in the control of
the reported FoxO-mediated regulation of cyclin D1 levels
required for cell transition from proliferative growth to quiescence
[63], we then compared cyclin D1 and FoxO1 expression in
KRIT12/2 and Lv-KRIT1 MEF cultures either pre-confluent
and exponential growing in complete medium (pre-confl/
10%FCS) or confluent and serum-starved (confl/0%FCS). As
shown in figure 7D, in pre-confluent, exponential growing cultures
Figure 6. siRNA-mediated knockdown of KRIT1 in HUVEC cells results in the downregulation of FoxO1 and SOD2mRNA expression.
HUVEC cells were transfected with either two distinct KRIT1-specific siRNA (siK655 and siK469) or a negative control siRNA (siNC). 48 hours post-
transfection, RNA was isolated and analyzed in triplicate by RT-qPCR using TaqManH gene expression assays specific for human KRIT1 (A), FoxO1 (B),
SOD2 (C), FoxO4 (D), SOD1 (E), and Cat (F) mRNA. 18S rRNA was used as an endogenous control for RT-qPCR normalization. Results are expressed as
relative mRNA level units referred to the average value obtained for negative control siRNA-treated samples, and represent the mean (6 SD) of n$3
independent RNAi experiments. *P,0.001 versus siNC. Notice that the knockdown of KRIT1 in HUVEC cells, although incomplete, was sufficient to
induce a significant downregulation of FoxO1 and SOD2 mRNA expression levels.
doi:10.1371/journal.pone.0011786.g006
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Figure 7. KRIT1 expression facilitates FoxO-mediated cell transition from proliferative growth to quiescence. A–D) Wild-type (WT),
KRIT12/2 (K2/2) and Lv-KRIT1 (K2/7, K10/6 and K9/6) MEFs were grown to confluence and either left untreated at confluence for 2 days (A–C),
stimulated to proliferate by replating at subconfluence in 10%FCS-containing medium for 2 hrs (D, pre-conf/10%FCS) or maintained at confluence in
serum-free medium for 18 to 20 h to induce cell cycle exit (D, post-confl/0%FCS). A) Western blot analysis of cyclin D1 expression in KRIT12/2 and Lv-
KRIT1 MEFs left at confluence for 2 days in complete medium. Tubulin was used as loading control. Notice that cyclin D1 protein levels are
significantly higher in KRIT12/2 than Lv-KRIT1 MEFs. B–C) RT-qPCR analysis of cyclin D1 (B) and p27Kip1 (C) mRNA expression levels. Results are
expressed as relative mRNA level units referred to the average value obtained for the KRIT12/2 (K2/2) samples, and represent the mean (6 SD) of
n$3 independent RT-qPCR experiments. *P,0.001 versus KRIT12/2 cells. Notice that the expression of KRIT1 facilitates the downregulation of cyclin
D1 and the upregulation of the cell cycle inhibitor p27Kip1 mRNA levels required for cell transition from proliferative growth to quiescence. D)
Western blot analysis of cyclin D1 expression in KRIT12/2 and Lv-KRIT1 MEFs allowed to proliferate (pre-conf/10%FCS) or to exit from the cell cycle
(post-confl/0%FCS). Tubulin was used as loading control. Notice that, while KRIT12/2 and Lv-KRIT1 proliferating cultures show similar levels of cyclin
D1 and FoxO1, the expression levels of cyclin D1 are significantly reduced in post-confluent/serum-starved Lv-KRIT1 but not KRIT12/2 cultures, and
this effect is associated with the upregulation of FoxO1 protein levels/activity. E–F) Equal number of KRIT12/2 (K2/2) and Lv-KRIT1 (K9/6) MEFs were
dispensed in 96-well microtiter plates and maintained in complete medium. E) The number of adherent cells was determined at different time
periods using the crystal violet staining method. Data are expressed as a percentage of the crystal violet absorbance at the zero-time point, deemed
as 100%, and represent the mean (6 SD) of the percentage increase of cell numbers from 5 independent experiments. F) Post-confluent (72 hrs) cell
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the expression levels of cyclin D1 were high and no significant
differences were detected between KRIT12/2 and Lv-KRIT1
MEFs (Fig. 7D, pre-confl/10%FCS, cyclin D1). Consistently,
under these cell culture conditions FoxO1 levels and activity were
low and very similar between KRIT12/2 and Lv-KRIT1 MEFs
(Fig. 7D, pre-confl/10%FCS, FoxO1). On the other hand, when
confluent, serum-starved cultures were analyzed, the expression
level of cyclin D1 in Lv-KRIT1 MEFs resulted significantly
reduced as compared to proliferating cultures (Fig. 7D, confl/
0%FCS, cyclin D1); moreover, this effect was strongly correlated
with the upregulation of FoxO1 protein levels and activity (Fig. 7D,
confl/0%FCS, FoxO1), suggesting that the FoxO1-mediated
regulation of cyclin D1 levels that controls cell transition from
proliferative growth to quiescence occurs normally in Lv-KRIT1
MEFs. In contrast, these responses were almost completely
abrogated in KRIT12/2 MEFs (Fig. 7D, compare pre-confl/
10%FCS and confl/0%FCS panels), indicating that the partici-
pation of KRIT1 is required.
To strengthen these findings, we examined changes in the total
number of cells during culture transitions from early to late stages of
cell confluence. At early confluence (24 hrs), the total number of
cells was similar in KRIT12/2 and Lv-KRIT1 MEF cultures
(Fig. 7E), suggesting that KRIT1 loss does not affect the rate of cell
proliferation. However, while the number of cells in post-confluent
(48–72 hrs) KRIT12/2 MEF cultures continued to increase,
indicating a reduced capacity of these cells to exit from the
proliferative cycle, the number of post-confluent (48–72 hrs) Lv-
KRIT1 MEFs remained almost constant (Fig. 7E), suggesting that
these cells exited from the proliferative cycle and maintained
quiescent growth. Furthermore, the different capacity of KRIT12/2
and Lv-KRIT1MEFs to successfully transit into quiescence from the
proliferative growth state was also evident from microscopic
examination of post-confluent cultures stained with the crystal violet
dye showing that KRIT12/2 MEFs were characterized by
significantly higher cell densities than Lv-KRIT1 MEFs (Fig. 7F).
Wilde type MEFs behaved similarly to K9/6 MEFs; therefore the
relative growth curve was omitted for simplicity.
Taken together, these results suggest that the expression of
KRIT1 facilitates the FoxO-mediated downregulation of cyclin
D1 and upregulation of p27Kip1 levels required for cell transition
from proliferative growth to quiescence.
ROS scavenging overcomes the upregulation of cyclin D1
and the reduced cell capacity to exit from the
proliferative cycle caused by KRIT1 loss
It has been reported that cell transition from proliferative
growth to quiescence is affected by intracellular ROS levels
[66,67], which in turn are influenced by the transcriptional activity
of FoxO proteins [28,29,41]. Considering our findings that loss of
KRIT1 is associated with both a decrease in FoxO1 protein
levels/activity and an increase in intracellular ROS levels (see
above), we next wondered whether the reduced capacity of
confluent KRIT12/2 MEFs to downregulate cyclin D1 levels and
exit from the proliferative cycle might be due to their inability to
maintain an appropriate ROS threshold level. To address this
question, we compared the expression levels of cyclin D1 and the
capacity to transit from proliferative growth to quiescence in
KRIT12/2 and Lv-KRIT1 MEFs grown to post-confluence either
in the absence or presence of the ROS scavenging agent N-
acetylcysteine (NAC). As compared with untreated cells, NAC-
treated cells exhibited reduced levels of intracellular ROS (Fig. 8A);
moreover, the significant differences between untreated KRIT12/2
and Lv-KRIT1 MEFs (Fig. 8A, dashed curves) were almost
completely abrogated upon NAC treatment (Fig. 8A, solid curves).
Importantly, these effects were strongly correlated with the
abrogation of the differences between KRIT12/2 and Lv-KRIT1
MEFs in both cyclin D1 levels (Fig. 8B) and cell numbers in post-
confluent cultures (Fig. 8C, solid lines), suggesting that the reduced
capacity of KRIT12/2MEFs to downregulate cyclin D1 expression
and successfully exit from the proliferative cycle may be attributable
to the inability to maintain an appropriate ROS threshold level.
Remarkably, the NAC treatment did not affect the differences in the
expression levels of FoxO1 and SOD2 occurring between
KRIT12/2 and Lv-KRIT1 MEFs (Fig. 8B), indicating that these
events are upstream of ROS accumulation.
Taken together, these results suggest that the expression of
KRIT1 facilitates the regulation of cyclin D1 levels required for
cell transition from proliferative growth to quiescence by
preventing the accumulation of intracellular ROS.
KRIT1 protects cells from oxidative stress-induced DNA
damage
It is well established that the major portion of oxidative stress
long term effects is inflicted by damage to DNA [32,68,69].
Conversely, FoxO proteins are known to act as major mediators of
cell defense against oxidative stress by regulating the expression of
proteins involved in ROS scavenging and repair of oxidative
damage [28,70]. Together with our findings, these considerations
prompted us to investigate whether KRIT1 plays a role in the
mechanisms that protect cells from ROS-induced DNA damage.
To address this question, we examined whether the observed
differences in intracellular ROS levels between KRIT12/2 and
Lv-KRIT1 MEFs were correlated with different amounts of the
DNA adduct 8-oxo-deoxyguanosine (8-oxo-dG), a well established
marker of oxidative DNA damage [32,71,72]. The outcomes of
this analysis showed a modest but statistically significant difference
in the basal levels of 8-oxo-dG between KRIT12/2 and Lv-
KRIT1 MEFs (Fig. 9A, untreated), which was further enhanced
upon acute oxidative stress induced by H2O2 treatment, leading to
a marked increase of 8-oxo-dG levels in KRIT12/2 MEFs as
compared with Lv-KRIT1 MEFs (Fig. 9A, H2O2 treated).
Remarkably, a negative correlation between KRIT1 and 8-oxo-
dG levels was also observed (Fig. 9A). On the other hand, NAC
pre-treatment to reduce the intracellular ROS levels (see Fig. 8A)
resulted in an almost complete abrogation of the differences in the
levels of 8-oxo-dG between KRIT12/2 and Lv-KRIT1 MEFs
(data not shown). These data indicate that KRIT1 protects cells
from the accumulation of oxidative damage to DNA as well as
against acute oxidative injury induced by oxidative stress stimuli.
To strengthen these findings, we examined additional markers
of ROS-induced DNA damage, including the phosphorylation
status of H2AX, an ubiquitous member of the H2A histone family
that is phosphorylated on serine 139 to yield a form known as c-
H2AX in response to oxidative stress-induced double-strand DNA
damage [73], and the mRNA levels of Gadd45a (growth arrest
and DNA damage-inducible gene 45 alpha), a stress sensor gene
whose transcription is induced in response to DNA damage caused
by both environmental and physiological stress, including
oxidative stress [74,75].
cultures were stained with crystal violet and photographed at 406microscope magnification. Notice the significant differences in cell number (E) and
cell density (F) between post-confluent KRIT12/2 and Lv-KRIT1 MEFs.
doi:10.1371/journal.pone.0011786.g007
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Western blot analysis of H2O2-challenged cells showed that
KRIT12/2 MEFs expressed higher levels of c-H2AX than Lv-
KRIT1 MEFs (Fig. 9B), further supporting the finding that
KRIT1 loss is associated with an increased cell susceptibility to
oxidative stress-induced DNA damage. Moreover, as measured by
RT-qPCR analysis, the level of Gadd45a mRNA was more than
5-fold higher in KRIT12/2 MEFs compared to Lv-KRIT1 MEFs
(Fig. 9C), suggesting that KRIT1 loss leads to a strong induction of
the DNA damage response gene Gadd45a.
Taken together with our previous findings, these results suggest
that KRIT1 loss/reduction leads to an accumulation of intracel-
lular ROS and oxidative DNA damage.
KRIT1 confers resistance to oxidative challenge-induced
apoptotic response
Besides DNA damage, excessive oxidative stress has been clearly
shown to trigger activation of redox-sensitive apoptotic pathways in a
ROS concentration- and cell context-dependent manner [76,77,78].
To test whether KRIT1 loss correlated with an enhanced cell
susceptibility to oxidative stress-induced apoptosis, we compared
apoptotic responses of KRIT12/2 and Lv-KRIT1MEFs challenged
with either inorganic or organic oxidants known to elicit apoptosis,
including H2O2 and tert-butyl hydroperoxide (TBHP) [77,79]. In
particular, as biochemical hallmark of apoptotic response to
oxidative stress we used the Western blot detection of the active
form of caspase-3 [80,81] as well as the TUNEL assay. As compared
with Lv-KRIT1MEFs, the level of proteolitic-cleaved, active form of
caspase-3 resulted significantly enhanced in KRIT12/2MEFs upon
either H2O2 (Fig. 10A) or TBHP (Fig. 10B) oxidative challenge,
indicating that KRIT1 loss is associated with an increased
susceptibility to caspase 3 activation during oxidative challenge.
Moreover, as assessed by the TUNEL assay, the number of
apoptotic cells was higher in hydroperoxide-challenged KRIT12/2
MEFs than in their Lv-KRIT1 counterparts (data not shown).
Taken together with the previous findings, these results suggest
that KRIT1 loss results in an increased cell susceptibility to
oxidative challenge-induced apoptotic response that correlates
with an impaired ROS homeostasis.
KRIT1 modulates mitochondrial homeostasis
ROS are produced at various intracellular sites, yet mitochon-
dria are considered the major endogenous source of superoxide
anions, peroxynitrite, and hydroxyl radicals, both in physiological
and pathological conditions, and are also targets for the damaging
effect of oxidants [82,83]. To assess whether mitochondria
contributed to the KRIT1 loss-dependent accumulation of
intracellular ROS levels, we used a semiquantitative fluorescence
microscopy method based on the MitoSOX Red mitochondrial
superoxide indicator, a novel fluorogenic probe recently developed
and validated for highly selective detection of superoxide in the
mitochondria of live cells [84]. Using this method we found that
the MitoSOX fluorescence intensity was significantly higher in
KRIT12/2 than in wild-type and Lv-KRIT1 MEFs (Supplemen-
tary Fig. S3), indicating the presence of enhanced mitochondrial
superoxide levels, and suggesting that the elevated steady-state
levels of intracellular ROS found in KRIT12/2 cells are likely due
to the impairment of mitochondrial superoxide homeostasis.
Because recent evidence suggests that mitochondrial ROS
accumulation may affect mitochondrial energy metabolism,
eventually resulting in a vicious cycle of redox-stimulated ROS
production [82], we next wondered whether mitochondrial
parameters were altered in KRIT12/2 MEFs as compared with
their wild-type and Lv-KRIT1 counterparts.
Figure 8. ROS scavenging overcomes the upregulation of
cyclin D1 and the reduced cell capacity to exit from the
proliferative cycle caused by KRIT1 loss. KRIT12/2 (K2/2) and Lv-
KRIT1 (K9/6) MEFs were grown to post-confluence either in the absence or
presence of the ROS scavenging agent N-acetylcysteine (NAC, 20 mM)).A)
Representative flow cytometry profiles of 5 independent FACS analyses of
the intracellular ROS levels in untreated (dashed curves) and NAC-treated
(solid curves) KRIT12/2 and Lv-KRIT1 MEFs, as detected by the DCFH-DA
probe. Notice that the significant differences in ROS levels between
untreated KRIT12/2 and Lv-KRIT1 MEFs were almost completely abrogated
upon NAC treatment. B) Western blot analysis of cyclin D1, FoxO1 and
SOD2 protein expression in untreated and NAC-treated KRIT12/2 and Lv-
KRIT1 MEFs. Tubulin was used as loading control. Notice that the NAC-
mediated abrogation of the differences in ROS levels between KRIT12/2
and Lv-KRIT1 MEFs correlates with the abrogation of the differences in
cyclin D1 but not FoxO1 nor SOD2 levels.C) Cell numbers in untreated and
NAC-treated post-confluent KRIT12/2 and Lv-KRIT1MEFs, as determined at
different time periods starting from early confluence using the crystal
violet staining method. Notice that the significant differences in cell
numbers occurring between untreated KRIT12/2 and Lv-KRIT1 MEFs
(dashed lines) are completely abrogated by the NAC treatment (solid lines).
doi:10.1371/journal.pone.0011786.g008
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To investigate the consequences of KRIT1 dowregulation
on mitochondrial Ca2+ signaling, we carried out a series of
experiments using a specifically targeted aequorin probe
(mtAEQ) to mitochondrial matrix [85]. When the cells were
stimulated with adenosine triphosphate (ATP), the P2 receptor
agonist that, by acting on a Gq-coupled P2Y receptor, causes
the production of inositol 1,4,5 trisphosphate and thus the
release of Ca2+ from the endoplasmic reticulum, rapid increases
in the mitochondrial Ca2+ concentration ([Ca2+]m) was observed
in all cases. In quantitative terms, however, the increases
of [Ca2+]m were drastically lower in KRIT1
2/2 (K2/2:
6,0960,31 mM) compared to KRIT1+/+ (wt: 11,6261,08 mM)
or KRIT12/2 re-expressing KRIT1 (K9/6: 10,7561, 25 mM)
MEFs (Fig. 11A,B).
As to the driving force for Ca2+ accumulation, the mitochon-
drial transmembrane potential (Dy) was then directly measured
with a Dym-sensitive dye [86]. Loading of the potential-sensitive
tetramethyl rhodamine methyl ester (TMRM) dye revealed a
significant difference in Dy in KRIT12/2 compared to KRIT1+/+
or KRIT12/2 re-expressing KRIT1 MEFs (Fig. 11C–E).
The most important role of Ca2+ signaling in mitochondria after
agonist stimulation (i.e. ATP) is the production of ATP through
the stimulation of mitochondrial dehydrogenases. This in turn
permits the control of ATP-regulated cell processes that rapidly
adapted aerobic metabolism to the increased needs of a stimulated
cell [87]. Thus, based on previous observations that stimulations
with agonists evoking mitochondrial Ca2+ signals cause parallel
increases in intracellular ATP [88], we also measured mitochon-
Figure 9. KRIT1 protects cells from oxidative stress-induced DNA damage. A) Confluent wild-type (WT), KRIT12/2 (K2/2GFP and K2/2), and
Lv-KRIT1 (K2/7, K10/6 and K9/6) MEFs were either left untreated (untreated) or treated with 0,5 mM H2O2 for 30 min (H2O2 treated) before DNA
extraction. 8-oxo-dG levels were measured by HPLC-EC as described in Materials and Methods. Values are the mean (6 SD) of 5 independent assays.
*P#0.001 versus KRIT12/2. Notice that a modest but significant accumulation of 8-oxo-dG was detected in KRIT12/2 MEFs as compared with KRIT1
re-expressing MEFs, which was further enhanced upon cell treatment with H2O2. B) Western blot analysis of phosphorylated histone c-H2AX
expression levels upon treatment of confluent KRIT12/2 (K2/2GFP and K2/2) and Lv-KRIT1 (K10/6 and K9/6) MEF cells with 0,5 mM H2O2 for 30 min.
KRIT1 protein levels in cell extracts were assessed using the K1 antibody (K1 pAb). The additional, undetermined 95 kDa band detected by this
antibody served as internal control for blot normalization. Notice that c-H2AX levels resulted higher in KRIT12/2 than KRIT1 re-expressing MEFs. C)
RT-qPCR analysis of Gadd45amRNA expression levels in confluent KRIT12/2 (K2/2) and Lv-KRIT1 (K2/7, K10/6 and K9/6) MEFs. Notice that the level of
Gadd45a mRNA was significantly elevated in KRIT12/2 MEFs as compared with Lv-KRIT1 MEFs.
doi:10.1371/journal.pone.0011786.g009
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drial ATP levels ([ATP]m) in KRIT1
+/+, KRIT12/2 and
KRIT12/2 re-expressing KRIT1 MEFs. For this purpose, the
mitochondria-targeted ATP probe luciferase (mtLUC) was
cotransfected, as previously reported [88]. As shown in Fig. 11F,
in agreement with the data presented in Fig. 11A, the increase in
[ATP]m evoked by agonist stimulation is significantly lower in
KRIT12/2 MEFs compared to those observed in KRIT1+/+ or
KRIT12/2 re-expressing KRIT1 MEFs.
Collectively, these results highlight a critical role of KRIT1
in the maintenance of mitochondrial homeostasis. Moreover,
taken together with previous findings, they suggest that the
reduced capacity to maintain appropriate ROS steady-state
levels and enhanced susceptibility to oxidative challenge of
KRIT12/2 MEFs are likely due to concurrent defective ROS
scavenging activity and decline of mitochondrial energy
metabolism.
Discussion
The maintenance of highly regulated mechanisms to control
intracellular levels of reactive oxygen species (ROS) is essential for
normal cellular homeostasis. Indeed, most ROS, including free
radicals and peroxides, are produced at low level by normal
aerobic metabolism and play an important role in the redox-
dependent regulation of many signaling processes [32,40,89]. In
contrast, excessive accumulation of ROS, resulting from an
imbalance between ROS production and scavenging, leads to a
condition of oxidative stress that can cause extensive oxidative
damage to all cellular components, including proteins, lipids, and
DNA, and may have pathophysiological consequences [32,40].
Remarkably, oxidative stress has been clearly implicated in the
pathogenesis of several human diseases, including cerebrovascular
diseases [26,39,90,91].
Here, we demonstrate that KRIT1, a protein whose loss-of-
function has been associated to the pathogenesis of the vascular
disease Cerebral Cavernous Malformations, is part of the
intracellular machinery that controls the redox balance. In
particular, we found that loss of KRIT1 leads to a significant
increase in intracellular ROS levels, while KRIT1 re-expression in
KRIT1-null cells rescues this effect in an expression level-
dependent manner. Moreover, we show that KRIT1 regulates
the expression of the superoxide anion (O2
?2) scavenging protein
SOD2, as well as of the transcriptional factor FoxO1, a master
regulator of cell responses to oxidative stress and a modulator of
SOD2 levels [29,92]. Furthermore, we show that the KRIT1-
dependent maintenance of low ROS levels facilitates the
downregulation of cyclin D1 expression required for cell transition
from proliferative growth to quiescence. Finally, we demonstrate
that KRIT1 loss is associated with an increased cell susceptibility
to oxidative DNA damage and apoptotic response as well as with a
marked transcriptional induction of Gadd45a, an oxidative DNA
damage sensor and repair gene involved in the promotion of
epigenetic events by repair-mediated DNA demethylation
[74,93,94], and a decline of mitochondrial energy metabolism.
Taken together, these findings suggest that KRIT1 may exert a
protective effect against oxidative stress by enhancing the cell
capacity to scavenge intracellular ROS through an antioxidant
pathway involving FoxO1 and SOD2, thus providing novel and
useful insights into the understanding of KRIT1 molecular and
cellular functions, and suggesting a novel potential mechanism for
CCM pathogenesis.
KRIT1 regulates the steady-state levels of intracellular
ROS
The superoxide anion (O2
?2) is a key determinant of the overall
effects of ROS. Indeed, even though O2
?2 has a short half-life, it is
highly reactive and can directly produce cellular injury by
inactivating proteins containing Fe-S centers. Moreover, it is the
uppermost mediator in the propagation of detrimental oxidative
chain reactions, being a precursor of all other major reactive
oxygen species found in biological systems, including the powerful
oxidants hydroxyl radical (?OH), hydrogen peroxide (H2O2), and
peroxynitrite (OONO2) [26,32,39,91].
O2
?2 is generated by a number of sources located throughout
the cell via the incomplete, one-electron reduction of molecular
oxygen (O2). Specifically, under physiological conditions, the
redox complexes I-III of the mitochondrial electron transport
chain are the major constitutive source, converting up to 5% of
molecular O2 to O2
?2 [83]. In addition, O2
?2 production is
induced by a variety of chemical and physical stimuli, includ-
ing growth factors, inflammatory cytokines, metabolic factors,
Figure 10. Krit1 confers resistance to redox-sensitive activation
of caspase-3. Confluent KRIT12/2 (K2/2) and Lv-KRIT1 (K9/6) MEFs
were either left untreated (Ctrl) or treated for 60 min with either
0,5 mM H2O2 (H2O2) (A) or 0,5 mM TBHP (TBHP) (B) before protein
extraction. The presence of the proteolitic-cleaved, active form of
caspase 3 (17 kDa), a hallmark of cell response to apoptotic stimuli, was
assessed by Western blot analysis as described in Materials and
Methods. Tubulin was used as loading control. Notice that, upon
oxidative challenge with either H2O2 or TBHP, the active form of
caspase-3 resulted significantly enhanced in KRIT12/2 than KRIT1 re-
expressing MEFs.
doi:10.1371/journal.pone.0011786.g010
KRIT1 Controls ROS Levels
PLoS ONE | www.plosone.org 13 July 2010 | Volume 5 | Issue 7 | e11786
Figure 11. Krit1 regulates mitochondrial homeostasis. A) Wild-type (WT), KRIT12/2 (K2/2) and KRIT1-transduced (K9/6) MEFs grown under
standard conditions were infected with the adenovirus expressing the mtAEQ chimera. After 36 h of expression cells were measured as described in
Material and Methods. Where indicated, the cells were stimulated with 100 mM ATP. The traces shown are representative of the kinetic of
mitochondrial Ca2+ responses. B) [Ca2+]m responses is represented as a percentage of the peak value of control cells. C) TMRM staining after 30
minutes loading at 37uC, as described in Materials and Methods. K2/2 cells showed a significant lower intensity fluorescent signal than WT and K9/6
MEFs clearly indicating a reduced mitochondrial membrane potential (Dy). D) Kinetics of tetramethyl rhodamine methyl ester (TMRM) fluorescence of
WT, K2/2 and K9/6 MEFs. FCCP (carbonyl cyanide p-trifluoromethoxyphenylhydrazone), an uncoupler of oxidative phosphorylation, completely
collapses the Dy. The traces are representative of single cell responses. E) Average variations of TMRM fluorescence of WT, K2/2 and K9/6 MEFs
treated with FCCP as calculated for six independent experiments and represented as a percentage of the value of WT cells. F) WT, K2/2 and K9/6
MEFs were infected with the adenovirus expressing the mtLUC chimera. The traces show mitochondrial ATP concentration ([ATP]m) changes elicited
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vasoactive neurotransmitters, shear stress, ischemia/reperfusion,
chemotherapeutics and ionizing radiations, as well as aging
[26,39,91,95,96]. Conversely, O2
?2 is rapidly removed by distinct
SOD isoenzymes, located in the mitochondria (SOD2), cytoplasm
(SOD1) and extracellular (SOD3) compartments, which catalyze
the dismutation of O2
?2 into H2O2 and O2 [97]. Importantly,
because O2
?2 can spontaneously react with nitric oxide (NO) to
form OONO2 at a rate 3 times faster than O2
?2 dismutation by
SOD, modest increases of O2
?2 can result in a great reduction of
NO bioavailability and increased formation of OONO2, a very
strong oxidant with the potential to produce multiple cytotoxic
effects [98,99]. In addition, OONO2 can also trigger feedforward
mechanisms that further amplify O2
?2 generation and oxidative
stress, including the uncoupling of NO synthase (NOS) which
produces O2
?2 instead of NO, thus amplifying the risk of cellular
dysfunction and oxidative injury [26]. The maintenance of O2
?2
homeostasis by SOD enzymes is therefore crucial for preventing
oxidative stress and ROS detrimental effects on cellular and tissue
functions. In particular, because of its subcellular localization, the
mitochondrial enzyme SOD2 is considered a first, crucial line of
defense against oxidative stress [97].
In this context, our finding that KRIT1 may enhance the cell
capacity to scavenge superoxide anions by modulating the
expression of the antioxidant gene SOD2 points to a major role
for KRIT1 in the intracellular machinery that controls the redox
balance. Furthermore, taken together with the reported role of
KRIT1 in the maintenance of the cell-cell and cell-matrix adhesion-
dependent barrier function of endothelial cells [12,13,15,16], as well
as with large body of evidence of oxidative stress-mediated
endothelial cell barrier disruption [90,100,101,102,103], our data
raise the hypothesis that KRIT1 may regulate the stability of
endothelial cell-cell and cell-matrix junctions by fine-tuning cellular
redox homeostasis through the maintenance of proper SOD2 levels.
Intriguingly, it has been reported that SOD2 levels are higher in
cerebral than in systemic vasculature [97,104], as well as that
astrocytes helps brain capillary endothelial cells in maintaining high
levels of SOD2 as a prerequisite for normal blood-brain barrier
(BBB) function [102]. Conversely, there is evidence for selective
cerebral microvascular endothelial dysfunction in SOD2-deficient
mice [105], suggesting that SOD2 is particularly important for
limiting basal O2
?2 levels in cerebral vasculature, which is required
to maintain the essential property of the BBB. Consistently,
enhanced O2
?2 levels have been demonstrated to play a major
role in endothelial dysfunction and vascular remodeling underlying
cerebrovascular diseases [26,95,98,106]. In this light, our findings
open a new avenue for studies in animal models and CCM patients
aimed at defining the role of oxidative stress in CCM pathogenesis.
KRIT1 regulates FoxO1 expression
FoxO transcription factors have emerged as master regulators of
genes involved in the control of a wide range of biological
processes, including apoptosis, cell cycle transitions, DNA damage
repair, defense against oxidative stress, cell differentiation, glucose
metabolism and lifespan [28,29,41,47]. These divergent functions
of FoxO proteins are regulated by multiple signaling pathways
acting at both the transcriptional and posttranslational levels
[47,54,107]. Intriguingly, depending on ROS intracellular levels
and the cell context, oxidative stress has been shown to regulate
most of the FoxO posttranslational modifications involved in the
modulation of its functions, including phosphorylation, acetyla-
tion, ubiquitination and interactions with other proteins, leading to
distinct outcomes [47,108,109,110,111,112,113]. In turn, FoxO
activity has been demonstrated to play a crucial role in cellular
defenses against oxidative stress by controlling the expression of
antioxidant proteins, such as SOD2, catalase and peroxiredoxin
III [28,41,42,43,44,114,115]. Hence, FoxO and oxidative stress
appear to be intricately connected. This connection is of particular
interest with respect to the reported role for FoxO factors in
vascular homeostasis [49,56]. In particular, there is clear evidence
that FoxO1 is the most important FoxO factor in the vasculature,
where it is essential for the regulation of endothelial cell barrier
function [49,50,51]. Notably, FoxO1 and KRIT1 knockout
animals share similar features. Indeed, at embryonic day E9.5
both FoxO1 and KRIT1 knockout animals exhibit defects of
the aortic arch arteries, dilatation of cerebral capillaries and
pericardial swelling as well as the downregulation of artery-specific
markers [14,49], suggesting a common pathogenetic mechanism.
In this light, our finding that KRIT1 regulates FoxO1
expression provides a unique connection between two fundamen-
tal players of vascular homeostasis within the intracellular
machinery that controls the redox balance.
Furthermore, our findings provide also some insights into the
mechanism underlying the modulation of FoxO1 expression/
activity by KRIT1, suggesting that the KRIT1 loss-dependent
downregulation of FoxO1 can be attributable, at least in part, to a
KRIT1 loss-dependent enhanced activation of Akt, which in turn
accelerates the FoxO1 phosphorylation-dependent inactivation
and degradation. Consistently, a seminal study in C. elegans [27],
reporting that a functional connection between kri-1, the worm
ortholog of KRIT1, and DAF-16, the worm ortholog of
mammalian FoxO genes, is required for germline removal-
dependent life span extension, has demonstrated that KRI-1
function is dispensable when DAF-16 is unphosphorylated on Akt-
consensus sites. In particular, although the molecular machinery
underlying the functional relationship between KRI-1 and DAF-
16 remained undefined, this study suggested that KRI-1 acts
mainly to promote DAF-16 nuclear localization by preventing or
counteracting its Akt-mediated phosphorylation [27]. On the
other hand, because we observed that KRIT1 loss leads to a
downregulation of FoxO1 at both mRNA and protein levels, the
KRIT1-dependent mechanism underlying the regulation of
FoxO1 expression might also imply a transcriptional control.
Intriguingly, recent evidence suggests that the posttranslational
control of FoxO1 can influence FoxO1 transcription. Indeed, a
conserved FoxO-binding site has been found in the promoter of
FoxO1 gene, and demonstrated to mediate the up-regulation of
FoxO1 by itself in a positive feedback loop [54], suggesting that,
besides prompting proteasomal degradation of the protein
[107,116], the phosphorylation-mediated inactivation of FoxO1
disrupts also a positive feedback mechanism whereby FoxO1
stimulates its own transcription [54]. Thus, in the light of the well
established link between life span extension and resistance to
oxidative stress, our findings that KRIT1 loss leads to an increased
Akt-primed phosphorylation and downregulation of FoxO1,
which correlates with a reduced cellular ability to detoxify
endogenous ROS and to counteract exogenous oxidative chal-
lenges, support and extend previous findings in C. elegans,
suggesting that KRIT1 might play a fundamental role at the
crossroad between resistance to oxidative stress and life span
extension.
by mitochondrial Ca2+ increase in cells perfused with 100 mM ATP as agonist. mtLuc luminescence data are expressed as a percentage of the initial
value. The traces are representative of n= 12 from three independent experiments.
doi:10.1371/journal.pone.0011786.g011
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In addition, the observation that KRIT1-dependent prevention
of Akt-mediated inactivation and downregulation of FoxO1 may
favor the interaction of FoxO1 with SirT1 raises the possibility
that KRIT1 plays a role in promoting the shifting of FoxO1
functions away from apoptosis and towards resistance to oxidative
stress. Consistently, SirT1 has been demonstrated to play a crucial
role in repressing FoxO1-induced apoptosis and potentiating
FoxO1-induced transcription of antioxidant and cell cycle arrest
genes, including SOD2 and p27Kip1 [58]. Conversely, there is
evidence that Akt activation sensitizes cells to ROS-mediated
apoptosis by inhibiting the expression of ROS scavengers
downstream of FoxO [117]. In this light, it is tempting to
speculate that the enhanced ability of KRIT1-expressing cells to
detoxify intracellular ROS is due to a molecular machinery
involving the KRIT1-dependent accumulation of unphosphory-
lated, active FoxO1 and the subsequent formation of a SirT1/
FoxO1 nuclear complex.
Finally, KRIT1 could also promote the stabilization and
function of FoxO1 by facilitating its interaction with b-catenin.
Consistent with this hypothesis, it has been demonstrated that
KRIT1 can bind b-catenin [15], whereas there is evidence that b-
catenin binds to FoxO and enhances FoxO transcriptional
activity particularly in response to oxidative stress signaling
[110,118]. Further studies, including studies based on compar-
ative gene profiling strategies, are required to better define the
likely complex molecular machinery that links KRIT1 to FoxO1
functions.
KRIT1 regulates cell transition from proliferative growth
to quiescence
It has been well established that ROS regulate positively
cellular proliferation by promoting either growth factor receptor
autophosphorylation or phosphatase inactivation [32,119].
Moreover, there is evidence that the cellular redox state
increases gradually towards a more oxidizing environment as
G1-cells move through the cell cycle [66]. Furthermore, it has
been reported that decreasing SOD2 activity favors cell
proliferation, while increasing SOD2 activity facilitates prolifer-
ating cells’ transitions into quiescence through the modulation of
cyclin expression [67]. The evidence that ROS are able to
regulate cellular proliferation is of particular interest if we
combine our finding that KRIT1 regulates intracellular ROS
levels with reported observations of endothelial cell proliferation
in CCM lesions and in the aorta of KRIT1 knockout mice
[14,19,120,121]. Indeed, in this light, our finding that the
expression of KRIT1 facilitates the FoxO-mediated downregu-
lation of cyclin D1 and upregulation of p27Kip1 levels required
for cell transition from proliferative growth to quiescence
suggests that KRIT1 plays a regulatory role in cell cycle
transitions through the modulation of intracellular ROS levels.
Accordingly, we demonstrate that the reduction of intracellular
ROS levels by cell treatment with the ROS scavenging agent
NAC overcomes the upregulation of cyclin D1 and the reduced
cell capacity to exit from the proliferative cycle caused by
KRIT1 loss. Furthermore, our finding that the NAC treatment
does not rescue the downregulation of FoxO1 and SOD2 levels
caused by KRIT1 loss demonstrates that both events are
upstream of ROS accumulation, suggesting a plausible molec-
ular pathway whereby the expression of KRIT1 facilitates the
downregulation of cyclin D1 levels required for cell transition
from proliferative growth to quiescence by preventing the
accumulation of intracellular ROS through the modulation of
FoxO1 and SOD2 levels.
KRIT1 protects cells from oxidative stress-induced DNA
damage
Excessive intracellular levels of ROS lead to an oxidative stress
condition that can damage cellular biomolecules, including DNA
[32]. Intriguingly, there is evidence for age-related increase in
oxidative stress and oxidative DNA damage in the cerebral
vasculature due to a progressive imbalance between antioxidant
defenses and intracellular concentrations of ROS [96,106,119].
Moreover, it has been shown that long periods of increased ROS
and consequent DNA damage are responsible of the complete loss
of the expression of some genes (i.e., double-hit) that accompanies
some genetic diseases, including vascular diseases and cancer [32].
In this context, our findings that KRIT1 plays an expression level-
dependent role in the regulation of ROS homeostasis, as well as a
protective role against oxidative DNA damage, raise the hypothesis
that a reduction of KRIT1 levels in heterozygous CCM mutation
carriers may facilitate DNA damage due to increased ROS levels,
leading to the loss of the second KRIT1 allele (second hit) and
resulting in the local formation of CCM lesions. Consistent with this
hypothesis, recent molecular and immunohistochemical data
provide good evidence that in some cases CCM lesion formation
involves a genetic two-hit mechanism in which a germline mutation
in one allele of a CCM gene is followed by a somatic mutation in
the other allele [19,20,21,22]. Furthermore, taken together with
recent evidence suggesting a role for the oxidative DNA damage
response gene Gadd45a in the promotion of epigenetic events by
repair-mediated DNA demethylation [74,93,94], our finding that
KRIT1 loss-of-function leads to a strong transcriptional induction
of Gadd45a suggests an additional potential oxidative stress-
mediated pathogenic mechanism for CCM.
KRIT1 modulates mitochondrial homeostasis and
apoptotic response
Using a fluorogenic probe developed and validated for highly
selective detection of superoxide in the mitochondria [84], we
found that mitochondria contributed to the KRIT1 loss-
dependent accumulation of intracellular ROS levels. Consistently,
most of the intracellular oxidative stress has been shown to
originate in mitochondria [82]. Indeed, enhanced levels of
mitochondrial superoxide anions due to defective SOD scavenging
activity have been demonstrated to cause mitochondrial dysfunc-
tions, including a decline of mitochondrial membrane potential,
electron transport chain activity, and energy metabolism, which,
in turn, induce a further increase in mitochondrial-produced
ROS, thus resulting in a vicious cycle of redox-stimulated ROS
formation that amplifies the risk of cellular oxidative damage
[82,122]. In this context, our findings that KRIT1 loss results in a
decline of mitochondrial energy metabolism as well as in an
enhanced cell susceptibility to oxidative challenge-induced apo-
ptotic response suggest that the reduced capacity to maintain
appropriate ROS steady-state levels and the consequent increased
susceptibility to oxidative damage that characterize KRIT12/2
cells are likely due to concurrent defects in mitochondrial ROS
scavenging activity and energy metabolism, thus providing
important additional information on KRIT1 cellular functions.
Conclusions
Taken together, our data demonstrate that KRIT1 regulates the
homeostasis of intracellular ROS through a molecular mechanism
involving the transcription factor FoxO1 and the antioxidant gene
SOD2, thus exerting a protective role against oxidative damage of
cell macromolecules, including DNA, and allowing a fine-tuned
control of cell cycle progression.
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Because it is well-established that oxidative stress challenge can
damage the vasculature by genetic, epigenetic or microenviron-
mental mechanisms [26], our findings would provide also a
plausible mechanistic explanation for the focal formation of CCM
lesions both in sporadic and familial cases. Indeed, a somatic or
germline mutation in one allele of a CCM gene would predispose
cells to an increased susceptibility to local events of oxidative stress,
eventually leading to the formation of a CCM lesion by either a
genetic, epigenetic or microenvironmental second hit event.
Moreover, this hypothesis would be consistent with the presence
of multiple CCM lesions in familial cases as well as with their
dynamic nature, and could also explain the incomplete clinical
penetrance, the variable expressivity, even among family members
carrying the same mutation, and the delayed, age-dependent onset
of the CCM disease. Notably, an increased ROS generation due to
the age-dependent uncoupling of endothelial NOS has been
recently associated with the late childhood and adult onset of the
CCM-related disease Hereditary Hemorrhagic Telangiectasia
[123]. Furthermore, taken together with the well-established
structural and functional heterogeneity and site-specificity of
endothelial cells [73], and with the evidence that the biological
effects of varying intracellular concentration of ROS depend on
cell context and genetically determined threshold levels [78], our
findings raise the possibility that in the presence of CCM
mutations the altered unique antioxidant properties of the
endothelial cells of some microvascular districts may selectively
combine with imbalanced microenvironmental oxidative cues,
thus contributing to the focal nature of CCM disease. Finally, our
hypothesis may also provide an alternative explanation to the
recently suggested effectiveness of statin drugs in the treatment of
CCM [25]. Indeed, while there is evidence that the Rho GTPase
pathway can be directly activated by ROS [90], it has been
demonstrated that, besides inhibition of Rho GTPases, the serum
cholesterol-lowering drug statins exert powerful intracellular
antioxidant activities in endothelial cells, including the inhibition
of superoxide production and the improvement of both ROS
scavenging and NO bioavailability [124,125].
In summary, our data describe a novel mechanism by which
KRIT1 controls the steady-state levels of intracellular ROS,
resulting in prevention of cellular oxidative damage, and raise the
hypothesis that CCM disease may result from an impaired
oxidative stress defense in specific microvascular districts of
genetically predisposed subjects, thus paving the way for further
research in animal models and CCM patients aimed at defining
the role of oxidative stress in CCM pathogenesis.
Materials and Methods
Ethics statement
Animals were kept under standardized temperature, humidity,
and lighting conditions with free access to water and food. Animal
care and experimental use followed the guidelines of the European
Council Directive 86/609/EEC (24 November 1986) and
Recommendation 2007/526/EC (18 June 2007), and were
approved by the ethics committee of the University of Torino
(Torino, Italy).
Targeted disruption of the KRIT1 gene
The KRIT1 gene was inactivated by homologous recombina-
tion deleting a 631 bp genomic region encompassing 77
nucleotides of the first exon, including the ATG codon, and
554 bp of the upstream 59 untranslated sequence, and replacing
this region with a pMC1-Neo-Poly(A) cassette. To construct the
targeting vector, a 7.8 Kb XbaI fragment derived from the 59-end
of a KRIT1 genomic clone was inserted into the XbaI site of
Bluescript SK vector upstream of the pMC1-Neo-Poly(A) cassette,
whereas a 3.8 Kb SmaI-SalI KRIT1 fragment starting from the
39-end of the first coding exon was inserted downstream.
E14.1 129/Ola Embryonic Stem (ES) cells, kindly provided by
Dr. Valeria Poli [126], were electroporated with the SalI
linearized targeting vector. Electroporated ES cells were selected
in tissue culture medium containing G418 and screened for
KRIT1 homologous recombination by EcoRV DNA digestion
and Southern blot hybridization using a 700 bp KRIT1 fragment
downstream of the targeting vector as probe. The predicted sizes
of the restriction fragments generated from the wild-type and the
recombinant allele were 16.8 Kb and 9.5 Kb, respectively
(Fig. 1A).
Two distinct 129/Ola ES cell clones positive for KRIT1
homologous recombination were obtained (Fig. 1B). Positive ES
cell clones were micro-injected into C57BL/6J blastocysts and
reimplanted into pseudopregnant foster mothers. Chimeric mouse
progeny was obtained and adult chimeric males were mated to
C57BL/6J females. Embryos and newborn mice were genotyped
by PCR analyses (Fig. 1C,D) using allele-specific primers.
Cell culture, lentiviral vector production, and cell
transduction
KRIT12/2 and KRIT1+/+ Mouse Embryonic Fibroblast (MEF)
cell lines were established from KRIT12/2 and KRIT1+/+ E8.5
mouse embryos, respectively, using the 3T3 protocol [30], and
cultured at 37uC and 5% CO2 in DMEM supplemented with 10%
FCS, 2 mM glutamine and 100 U/ml penicillin/streptomycin.
Human Umbilical Vein Endothelial Cells (HUVECs), pur-
chased from Lonza (CC-2519, Lonza Group Ltd, Switzerland),
were cultured on gelatine-coated dishes in M199 medium (Sigma)
supplemented with 10% FCS, 10 mg/ml heparin, endothelial cell
growth supplement (ECGS, Sigma), glutamine and antibiotics.
Each culture was used only up to eight population doublings.
A KRIT1A-expresssing lentiviral construct was generated
from the HIV-derived self-inactivating transfer construct
pCCLsin.PPT.PGK.EGFP.Wpre (provided by L. Naldini, HSR-
TIGET) by replacing the GFP cassette with the murine KRIT1A
cDNA [127]. Lentiviral vector particles were produced in 293T
packaging cells, transiently cotransfected with a mix of transfer,
envelope, and core-packaging constructs, as described previously
[31].
To obtain KRIT1-null and KRIT1-expressing MEF cells with
uniform genetic backgrounds to be used for comparative
molecular and cellular biology studies, distinct KRIT12/2 MEF
clones were infected with a lentiviral vector encoding either
KRIT1 (pCCLsin.PPT.PGK.KRIT1.Wpre), to restore KRIT1
expression, or GFP (pCCLsin.PPT.PGK.EGFP.Wpre) as a
control. The efficiency of distinct infections, evaluated as
percentage of GFP positive cells, was always greater that 80%.
Gene silencing experiments
The expression of KRIT1 in HUVEC cells was silenced by the
RNA interference (RNAi) technology using two distinct short
interfering double stranded RNA oligomers (siRNAs), SilencerH
Validated #15655 (siK655) and #15469 (siK469) siRNAs
(Ambion), corresponding to exon 12 and exon 9 sequences
(GenBank accession nu NM_194455), respectively. The BLOCK-
iTTM Alexa FluorH Red Fluorescent Oligo (Invitrogen) was used
for determination of efficiency of siRNA transfection as well as
RNAi negative control along with the SilencerH Negative Control
#1 siRNA (Ambion). Cells were reverse transfected with 30 nM
KRIT1-specific or Negative Control siRNAs using the AmaxaH
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HUVEC NucleofectorH Kit and electroporation device (Lonza)
according to the optimized manufacturer’s reverse transfection
protocol. Briefly, cells were harvested by trypsinization and cell
density was determined using the CountessTM automated cell
counter (Invitrogen). 56105 cells per sample were pelleted,
resuspended in 100 ml of supplemented HUVEC NucleofectorH
solution, combined with the appropriate dilution of siRNAs,
electroporated using the U-001 NucleofectorH program, and
seeded in 6-well plates containing complete culture medium. 48–
72 hours post-transfection, cells were lysed and analyzed by real-
time quantitative PCR (RT-qPCR).
Antibodies and Western blot analysis
Two rabbit polyclonal antibodies against KRIT1 (pAb K1 and
pAb K2) were produced by a standard rabbit immunization
procedure with a KRIT1 207 amino acid N-terminal fragment
[128] fused to a MBP tag, and purified by affinity chromatography
using a GST- K207NT fusion protein conjugated to a sepharose
column. The reactivity, specificity and sensitivity of these
antibodies for endogenous KRIT1 protein were tested by Western
blotting using KRIT12/2 cells as negative controls (Fig. 2A). In
particular, the K1 pAb showed a higher sensitivity than K2 pAb,
and, besides the specific 80 kDa KRIT1 band, detected an
additional, undetermined 95 kDa band that served as internal
control for blot normalization.
Other primary antibodies included rabbit mAbs against FoxO1
(2488 and 2880, Cell Signaling), SirT1 (3931, Cell Signaling) and
Acetylated-Lysine (9814, Cell Signaling); rabbit pAbs against
FoxO1/4 (9462, Cell Signaling)¸ FoxO3a (9467, Cell Signaling),
phospho-FoxO1/FoxO3a (9464, Cell Signaling), phospho-c-
H2A.X (S139) (11174, Abcam), Cyclin D1 (H-295, Santa Cruz
Biotechnology), SOD1 (FL-154, Santa Cruz), phospho-Akt
(Ser473) (9271, Cell Signaling), Cleaved Caspase-3 (9661, Cell
Signaling); goat pAb against Catalase (N-17, Santa Cruz); mouse
mAbs against SOD2 (16956, Abcam), Tubulin (T5168, Sigma),
Akt (19G7, Alexis) and b-Catenin (14, BD Transduction
Laboratories). Primary antibodies were detected using affinity
purified HRP-conjugated secondary antibodies (Sigma).
Immunoprecipitation and Western blotting analyses were
performed as previously described [129]. Briefly, for immunopre-
cipitation analysis, cell lysates containing equal amounts of total
proteins (,2 mg) were incubated overnight at 4uC with the
appropriate dilutions of specific antibodies and a mixture of
protein A- and protein G-Sepharose beads. Thereafter, beads were
washed 4 times with lysis buffer, and immunoprecipitated proteins
were eluted with Laemmli buffer and subjected to SDS-PAGE
followed by electroblotting onto ProtranH nitrocellulose transfer
membrane (Whatman). Whole cell lysates containing equal
amounts of total proteins (,50 mg) were separated by either
10% or 12% SDS-PAGE and electroblotted. The blots were
blocked with 5% BSA in Tris-buffered saline (TBS) containing
0.1% Tween 20 for 1 hour at 42uC, incubated with appropriate
dilutions of primary antibodies overnight at 4uC and subsequently
with HRP-conjugated secondary antibodies for 2 hours at room
temperature (RT). Proteins were then visualized by an enhanced
chemiluminescence (ECL) detection system (Millipore).
Real-Time quantitative PCR
DNA-free RNA was obtained by purification from cell
monolayers using the PureLink RNA Mini Kit and DNase I
treatment (Invitrogen), and used for cDNA synthesis with the
High-Capacity cDNA Reverse Transcription Kit (Invitrogen)
according to the manufacturer’s instructions. To quantify
transcript expression levels, an optimal TaqManH real-time PCR
assay was designed for each target transcript using the Probe-
Finder software (version 2.45) of the Universal Probe Library from
Roche. TaqManH gene expression assays were performed in
triplicate on MicroAmpH 96-well optical plates using a 7300 Real
Time PCR System (Applied Biosystems). Reactions were carried
out in 25 ml, containing 8 ml diluted (1:10) cDNA, 12,5 ml 26
qPCR Master Mix (Invitrogen), 0.2 ml each primer (20 mM)
(Sigma), 0.2 ml Probe (10 mM) (Roche), and 3.9 ml H2O, using the
following parameters: 50uC for 2 min, 95uC for 2 min, and 45
cycles of 90uC for 15 sec and 60uC for 30 sec. The amounts of the
target gene expressed in a sample were normalized to the amounts
of internal normalization controls, including the endogenous
‘house-keeping’ 18S rRNA and GAPDH (glyceraldehyde 3-
phosphate dehydrogenase) transcripts. All TaqMan PCR data
were collected using the Sequence Detector Software (SDS v1.3.1,
Applied Biosystems).
Fluorimetric measurement of intracellular ROS
Qualitative and quantitative analyses of intracellular ROS levels
were performed using a well-established method based on the cell-
permeable ROS-sensitive fluorogenic probes 29,79-dichlorofluor-
escin diacetate (DCFH-DA) and dihydroethidium (DHE), which
have a sensitivity for various ROS/RNS and superoxide anions
(O2
?2), respectively [33,34,35,36]. Briefly, cells grown to conflu-
ence in complete medium were washed twice with PBS, incubated
with DCFH-DA or DHE at a final concentration of 5 mM in PBS
at 37uC for 20 min, and analyzed by fluorescence microscopy and
flow cytometry.
For qualitative fluorescence microscopy analyses, cells treated
with the ROS-sensitive fluorogenic probes were washed twice with
PBS, and examined on a Zeiss Axiovert 200M fluorescence
microscope equipped with a MicroMAX:512BFT cooled CCD
camera (Princeton Instruments) and MetaMorph software for
hardware control and image acquisition. Images were taken with a
fixed short exposure time and a high fluorescence intensity
threshold value to avoid saturation.
For quantitative flow cytometry analyses, cells treated with the
ROS-sensitive fluorogenic probes were washed twice, trypsinized,
resuspended in PBS, and immediately analyzed on a FACScan
flow cytometer (Becton Dickinson). Intracellular ROS levels were
assessed as the mean fluorescence intensity (M.F.I) of 29,79-
dichlorofluorescin (DCF) and ethidium (Eth), the oxidation
products of DCFH-DA and DHE, respectively [33,34,35,36].
DCF green fluorescence (FL1-H channel) and Eth red fluores-
cence (FL2-H channel) of 10,000 cells were analyzed using the
Cell Quest software (Becton Dickinson).
Semiquantitative detection of mitochondrial superoxide was
performed using MitoSOXTM Red (Invitrogen), a fluorigenic dye
[3,8-phenanthridinediamine, 5-(69-triphenylphosphoniumhexyl)-
5,6 dihydro-6-phenyl] recently developed and validated for highly
selective detection of superoxide in the mitochondria of live cells
by fluorescence microscopy [84]. MitoSOXTM Red is live-cell
permeant and is rapidly and selectively targeted to mitochondria.
Once in the mitochondria, it is oxidized by superoxide, but not by
other ROS- or reactive nitrogen species (RNS)–generating
systems, and exhibits red fluorescence. Experiments were
performed according to manufacturer’s instructions (Molecular
ProbesTM, Invitrogen). Briefly, cells grown to 50–80% confluence
on glass bottom dishes or coverslips were allowed to load
MitoSOX, added to a final concentration of 5 mM in Hank’s
Buffered Salt Solution containing calcium and magnesium
(HBSS), for 15 min at 37uC in a CO2 incubator. Cells were then
washed two times with HBSS, counterstained with a blue
fluorescent nuclear dye (Hoechst 34580), and immediately imaged
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(cells grown on glass bottom dishes) or fixed with 3,7%
paraformaldehyde and mounted on microscope slides with
ProLongH Gold antifade reagent (Molecular ProbesTM, Invitro-
gen) before imaging (cells grown on glass coverslips). Confocal
microscopy imaging was performed on a Leica TCS_SP5 confocal
microscope (Leica Microsystems) using a PlanApo 636/1.40 oil
immersion objective, an Ar 100 mW, 514 nm excitation laser, and
a 580630 nm fluorescence detection range. Instrument parame-
ters for sequential image acquisition, including pinhole diameter,
laser intensity, exposure time, PMT gain and offset, were set and
held constant to minimize autofluorescence and for comparison
between samples.
Cell Proliferation Assay
Cell proliferation assays were performed using a colorimetric
method based on crystal violet staining [130]. Briefly, cells were
plated at a density of 2000 cells per well in 96-well microtiter plates
and either left untreated or treated with the ROS scavenger N-
acetylcysteine (NAC) (20 mM) in complete medium at 37uC for
different time periods. Cells were then fixed and stained with a
crystal violet solution (20% methanol, 0.2% crystal violet) for
30 min. Excess dye was removed by three brief rinses with ddH2O
and plates were allowed to air dry. For quantization of adherent
cell number, the cell-associated dye was solubilized by incubation
with a 10% acetic acid solution for 1 hour at room temperature,
and quantified by measuring its absorbance at 590 nm with a
microplate reader (Mithras LB 940, Berthold technologies). As
crystal violet absorbance at 590 nm is proportional to the total
number of adherent cells [130], cell numbers were expressed as a
percentage of the absorbance at the zero-time point, deemed as
100%. Cell densities in post-confluent cultures were examined by
staining cell monolayers with crystal violet and taking pictures at
406microscope magnification.
Quantitative measurement of 8-oxo-deoxyguanosine
The levels of the DNA adduct 8-oxo-dG, an established marker
of oxidative DNA damage, were determined by high-performance
liquid chromatography with electrochemical detection (HPLC/
EC) as previously described [71] with minor modifications. Briefly,
cells were harvested by trypsinization and incubated in lysis buffer
(10 mM Tris-HCl, 0.1 M EDTA, 0.5% SDS, 100 mg/ml
Proteinase K, pH 8.0) overnight at 37uC. To purify DNA, cell
lysates were added with 0.6 volumes of 5 M NaCl (in 40 mM
Tris, 20 mM EDTA, 0.3 mM deferoxamine mesylate (DFOM),
pH 8.0) and vigorously vortexed for 20 seconds. Following
centrifugation at 4000 rpm for 20 min, the clear supernatant
fraction was transferred to another tube, and 0.4 volumes of SE
buffer (75 mM NaCl, 25 mM EDTA, pH 8) were added along
with 1 volumes of Sevag (Chloroform: Isoamyl alcohol - 24:1).
Tubes were then placed in a vertical rocker at low speed (to ensure
mixing of organic and water phases) for 45 min, and centrifuged
for 15 min at 2500 rpm. The upper aqueous phase was then
transferred to another tube, and DNA was precipitated by
addition of 2 volumes of cold (220uC) ethanol and gentle mixing,
washed with cold 70% ethanol, and air dried.
For 8-oxo-dG determinations, DNA pellets were dissolved in
30 mM DFOM solutions and digested with 2–4 units Nuclease P1
and 10 units alkaline phosphatase at 50uC for 1 hr. Samples were
prepurified through micropure EZ filters and transferred to HPLC
autosampler vials. Separation of digested DNA components was
accomplished with a Beckman System Gold HPLC apparatus
equipped with diode array UV detection. Normal nucleosides
were detected at 254 and 290 nm. Electrochemical detection of
8-oxo-dG was performed with an ESA Coulochem II detector.
Guard, conditioning and 5011 high sensitive analytical cell were in
line with graphite filter elements. Solvent system consisted of 5%
MeOH and 95% 50 mM potassium phosphate. Flow rate was
0.5 ml/min. The LC-18-DB (Supelco, 7564.6 mm) analytical
column was equipped with a YMC ODS-AM 12 nm 5 mm guard
column. The Beckman’s Karat analytical software was used for
data analysis.
Detection of apoptotic response to oxidative stress
Cells grown in complete culture medium were either left
untreated or treated for different time periods (30 min–12 hrs)
with 0,5 mM of either hydrogen peroxide (H2O2) or tert-butyl
hydroperoxide (TBHP). Cells were then lysed and cell lysates were
analyzed by Western blotting for the presence of the proteolitic-
cleaved, active form of caspase-3 (17 kDa fragment).
The terminal deoxynucleotidyl transferase-mediated dUTP
nick-end-labeling (TUNEL) assay for detection of cells undergoing
apoptosis was performed using the In Situ Cell Death Detection
Kit, TMR red (Roche) according to the manufacturer’s instruc-
tions. Cells were counterstained with a blue fluorescent nuclear
dye (Hoechst 34580) and analyzed by fluorescence microscopy.
Aequorin measurements
All measurements were carried out as previously described [85].
Briefly, for the experiments with mtAEQ cells were incubated with
5 mM coelenterazine for 1–2 h in DMEM supplemented with 1%
FCS.
Mitochondrial membrane potential measurements
Electron negative changes in mitochondrial membrane poten-
tial were evaluated with the potential sensitive dye TMRM.
Experiments were performed with laser scanning confocal
microscopy at high magnification. Basal levels were normalized
on fluorescence in presence of the strong uncoupler FCCP.
Luciferase measurements
Cell luminescence was measured in the same purpose-built
luminometer used for the aequorin measurements. Cells were
constantly perfused with KRB, supplemented with 1 mM CaCl2
and 20 mM luciferin. All additions were made to this medium, as
specified in the figure legend. The light output of a coverslip of
infected cells was in the range of 1,000 –10,000 counts per second
(cps) versus a background lower than 10 cps. All compounds
employed in the experiments were tested for non-specific effects on
the luminescence and none were observed.
Statistics
Data are expressed as mean 6 SD. Statistical analyses were
performed by one-way analysis of variance (ANOVA) followed by
Bonferroni correction. P,0.01 was used as the threshold for
statistically significant differences.
Supporting Information
Supplementary Figure S1 The PI3K/Akt pathway is involved
in the KRIT1 loss-dependent downregulation of FoxO1 expres-
sion levels. A–B) Western blot analysis of phospho-Akt levels in
KRIT12/2 (K2/2) and Lv-KRIT1 (K9/6) MEFs. (A) Cells were
grown under standard conditions (Post-confl and Pre-confl) or
serum-starved overnight (Starved) before lysis. (B) Cells were
grown to confluence under standard conditions and either left
untreated (0) or treated with 0,5 mM H2O2 for the indicated time
periods before lysis. Phospho-Akt (p-Akt) levels were determined
with an antibody to phospho-serine 473. Total Akt (Akt) served as
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loading control. Notice that the levels of the phosphorylated form
of Akt are higher in KRIT12/2 MEFs than in their Lv-KRIT1
counterparts both under standard culture conditions [A and B
(0 min)] and upon oxidative challenge with H2O2 (B). C–D)
Western blot analysis of FoxO1 protein expression in confluent
KRIT12/2 (K2/2) and Lv-KRIT1 (K9/6) MEFs. (C) Cells grown
to confluence in standard culture conditions were serum-starved
overnight and either left untreated (-FCS), or treated with 10%
FCS for 15 min (+FCS) either in the absence (-LY) or in the
presence (+LY) of the PI3K/Akt pathway inhibitor LY294002
(40 mM in DMSO) before lysis. When used, LY294002 was added
30 min before and maintained during the FCS treatment. DMSO
and Tubulin served as vehicle and loading control, respectively.
(D) KRIT12/2 (K2/2) cells grown to confluence in standard
culture conditions were either serum-starved overnight (-FCS,
-LY), or rinsed with fresh medium (containing 10% FCS) and left
overnight (16 hrs) in the absence (+FCS, -LY) or in the presence
(+FCS, +LY) of LY294002 (40 mM in DMSO) before lysis.
Phospho-Akt (p-Akt) levels were determined with an antibody to
phospho-serine 473. Total Akt (Akt) served as loading control.
Notice that the LY294002 short-term treatment resulted in the
abrogation of the phosphorylation-dependent electrophoretic
mobility shift of FoxO1 induced by acute serum stimulation (C),
whereas the LY294002 long-term treatment counteracted the
serum-dependent FoxO1 downregulation (D).
Found at: doi:10.1371/journal.pone.0011786.s001 (1.48 MB
TIF)
Supplementary Figure S2 KRIT1 does not influence the
expression of SirT1 but favors its interaction with FoxO1.
KRIT12/2 (K2/2) and Lv-KRIT1 (K9/6) MEFs grown to
confluence under standard conditions were analyzed by co-
immunoprecipitation and Western blotting as described in
Materials and Methods. SirT1 was immunoprecipitated from cell
lysate supernatants with a SirT1-specific mAb (IP: SirT1), and
SirT1 immunocomplexes were analyzed by Western blotting with
antibodies against the indicated proteins, along with whole cell
lysates (Tot. Extract). Notice that KRIT1 neither interacted with
SirT1 nor influenced its expression. On the contrary, a modest but
significant co-immunoprecipitation of FoxO1 with SirT1 was
observed in KRIT1-expressing MEFs but not in KRIT12/2
MEFs.
Found at: doi:10.1371/journal.pone.0011786.s002 (0.48 MB TIF)
Supplementary Figure S3 KRIT1 regulates mitochondrial
superoxide homeostasis. A-B) Qualitative detection of the steady-
state levels of intracellular ROS by fluorescence microscopy. Wild-
type (WT), KRIT12/2 (KRIT12/2) and KRIT1-transduced (Lv-
KRIT1 9/6) MEFs grown under standard conditions were
analyzed by fluorescence microscopy 20 min after the addition
of the cell-permeable redox-sensitive fluorogenic probe DCFH-
DA (A) or DHE (B). The images were taken with a fixed short
exposure time and a high fluorescence intensity threshold value to
avoid saturation, and are representative of several independent
experiments. Notice that KRIT12/2 cells (panels b) showed
significantly more intense fluorescent signals than WT cells (panels
a), indicating that they contained higher levels of ROS.
Conversely, ROS levels in KRIT12/2 cells were reduced to near
WT levels upon KRIT1 re-expression by lentiviral infection
(panels c). Scale bar represents 50 mm.
Found at: doi:10.1371/journal.pone.0011786.s003 (1.87 MB TIF)
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